<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>My MS Log</title>
	<atom:link href="http://mymslog.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://mymslog.com</link>
	<description>Tracking your MS needs</description>
	<pubDate>Wed, 10 Mar 2010 15:25:19 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Results of Phase II &#8220;CHOICE&#8221; Study Published</title>
		<link>http://mymslog.com/news/results-of-phase-ii-choice-study-published/</link>
		<comments>http://mymslog.com/news/results-of-phase-ii-choice-study-published/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 15:25:19 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=79</guid>
		<description><![CDATA[Results of Phase II &#34;CHOICE&#34; Study Published, Showing that Daclizumab Reduced Disease Activity in Relapsing MS, and Revealing Novel Immune Mechanism

230 people with relapsing MS taking interferon beta and having disease activity were administered one of two doses of daclizumab (Biogen Idec and Facet Biotech Corp.) or placebo - show that the higher dose reduced [...]]]></description>
			<content:encoded><![CDATA[<h3><b><span lang="EN-CA" style="font-size:11.0pt;font-family:<br />
Arial;color:black">Results of Phase II &quot;CHOICE&quot; Study Published, Showing that Daclizumab Reduced Disease Activity in Relapsing MS, and Revealing Novel Immune Mechanism</span><font class="Apple-style-span" face="Arial" size="4"><span class="Apple-style-span" style="font-size: 15px;"><b><br />
</b></span></font></b></h3>
<p class="MsoNormal"><span lang="EN-CA" style="font-size:11.0pt;font-family:Arial;<br />
color:black">230 people with relapsing MS taking interferon beta and having disease activity were administered one of two doses of daclizumab (Biogen Idec and Facet Biotech Corp.) or placebo - show that the higher dose reduced disease activity on MRI scans by 72% and the lower dose by 25%. Immune analyses show that this reduction was associated with a dramatic increase in CD56bright NK cells - an unexpected finding. Daclizumab is a laboratory-created monoclonal antibody that blocks the activity of interleukin-2 receptor-alpha, a key immune activator in MS. The drug is approved for use in organ transplant rejection.&nbsp;<strong><span style="font-family:Arial">The Lancet Neurology, Early Online Publication, 16 February 2010</span></strong><o:p></o:p></span><font class="Apple-style-span" face="Arial" size="4"><span class="Apple-style-span" style="font-size: 15px;"><br />
</span></font></p>
<p class="MsoNormal"><b><span lang="EN-CA" style="font-size:11.0pt;font-family:<br />
Arial;color:black"><a href="http://www.mssociety.ca/en/research/medmmo_20100304.htm" target="_blank">http://www.mssociety.ca/en/research/medmmo_20100304.htm</a></span></b><span lang="EN-CA" style="font-size:11.0pt;font-family:Arial;color:black"><o:p></o:p></span></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/news/results-of-phase-ii-choice-study-published/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Les résultats de la phase II de l’étude CHOICE indiquent une réduction</title>
		<link>http://mymslog.com/news/les-resultats-de-la-phase-ii-de-l%e2%80%99etude-choice-indiquent-une-reduction/</link>
		<comments>http://mymslog.com/news/les-resultats-de-la-phase-ii-de-l%e2%80%99etude-choice-indiquent-une-reduction/#comments</comments>
		<pubDate>Tue, 09 Mar 2010 15:23:19 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=71</guid>
		<description><![CDATA[
Les r&#233;sultats de la phase II de l&#8217;&#233;tude CHOICE indiquent une r&#233;duction de l&#8217;activit&#233; de la maladie sous l&#8217;effet du daclizumab chez des patients atteints d&#8217;une forme r&#233;mittente de SP, en plus de r&#233;v&#233;ler un m&#233;canisme immunitaire jamais observ&#233; auparavant
&#160;
Au cours de cet essai clinique, 230&#160;personnes atteintes d&#8217;une forme r&#233;mittente de SP, trait&#233;es par l&#8217;interf&#233;ron [...]]]></description>
			<content:encoded><![CDATA[<p><span class="Apple-style-span" style="font-family: 'times new roman', 'new york', times, serif; font-size: 16px; "></p>
<p class="MsoNormal" style="margin-right: 0in; margin-left: 0in; font-size: 11pt; font-family: sans-serif; margin-top: 0in; margin-bottom: 0.0001pt; "><b><br />
</b><strong><span lang="FR" style="font-family: sans-serif; ">Les r&eacute;sultats de la phase II de l&rsquo;&eacute;tude CHOICE indiquent une r&eacute;duction de l&rsquo;activit&eacute; de la maladie sous l&rsquo;effet du daclizumab chez des patients atteints d&rsquo;une forme r&eacute;mittente de SP, en plus de r&eacute;v&eacute;ler un m&eacute;canisme immunitaire jamais observ&eacute; auparavant</span></strong></p>
<p class="MsoNormal" style="margin-right: 0in; margin-left: 0in; font-size: 11pt; font-family: sans-serif; margin-top: 0in; margin-bottom: 0.0001pt; "><strong><span lang="FR" style="font-family: sans-serif; ">&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin-right: 0in; margin-left: 0in; font-size: 11pt; font-family: sans-serif; margin-top: 0in; margin-bottom: 0.0001pt; "><span lang="FR" style="font-family: sans-serif; ">Au cours de cet essai clinique, 230&nbsp;personnes atteintes d&rsquo;une forme r&eacute;mittente de SP, trait&eacute;es par l&rsquo;interf&eacute;ron b&ecirc;ta et pr&eacute;sentant des signes d&rsquo;activit&eacute; de la maladie ont re&ccedil;u soit l&rsquo;une ou l&rsquo;autre des deux doses de daclizumab (Biogen Idec et Facet Biotech Corp.) &agrave; l&rsquo;&eacute;tude, soit un placebo. Les clich&eacute;s IRM r&eacute;alis&eacute;s dans le cadre de cet essai ont permis de constater que la plus forte des deux doses avait permis une r&eacute;duction de l&rsquo;activit&eacute; de la maladie de 72&nbsp;%, alors que la plus faible dose avait r&eacute;duit cette activit&eacute; de 25&nbsp;%. Aussi, les analyses portant sur la r&eacute;action immunitaire ont r&eacute;v&eacute;l&eacute; que cette r&eacute;duction &eacute;tait associ&eacute;e &agrave; une augmentation importante du nombre de cellules tueuses naturelles CD56 de forte expression (dites CD56bright), ce qui constitue une observation inattendue. Le daclizumab est un anticorps monoclonal synth&eacute;tis&eacute; en laboratoire dont l&rsquo;action consiste &agrave; bloquer l&rsquo;activit&eacute; du r&eacute;cepteur alpha de l&rsquo;interleukine-2 (IL-2), consid&eacute;r&eacute; comme un activateur cl&eacute; de la r&eacute;ponse immunitaire dans la SP. L&rsquo;utilisation de ce m&eacute;dicament a d&eacute;j&agrave; &eacute;t&eacute; approuv&eacute;e pour pr&eacute;venir le rejet de greffes.&nbsp;</span><em><b><span lang="EN-CA" style="font-family: sans-serif; ">The Lancet Neurology</span></b></em><strong><span lang="EN-CA" style="font-family: sans-serif; ">, version &eacute;lectronique publi&eacute;e le 16 f&eacute;vrier 2010</span></strong></p>
<p class="MsoNormal" style="margin-right: 0in; margin-left: 0in; font-size: 11pt; font-family: sans-serif; margin-top: 0in; margin-bottom: 0.0001pt; "><strong><span lang="EN-CA" style="font-family: sans-serif; ">&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin-right: 0in; margin-left: 0in; font-size: 11pt; font-family: sans-serif; margin-top: 0in; margin-bottom: 0.0001pt; "><b><a rel="nofollow" target="_blank" href="http://www.mssociety.ca/fr/recherche/medmmo_20100303.htm" style="color: blue; text-decoration: underline; ">http://www.mssociety.ca/fr/recherche/medmmo_20100303.htm</a></b></p>
<p></span></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/news/les-resultats-de-la-phase-ii-de-l%e2%80%99etude-choice-indiquent-une-reduction/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Multiple Sclerosis (MS) Information and news</title>
		<link>http://mymslog.com/news/multiple-sclerosis-ms-information-and-news/</link>
		<comments>http://mymslog.com/news/multiple-sclerosis-ms-information-and-news/#comments</comments>
		<pubDate>Fri, 05 Mar 2010 13:50:56 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[News]]></category>

		<category><![CDATA[chernobyl multiple sclerosis]]></category>

		<category><![CDATA[cis multiple sclerosis]]></category>

		<category><![CDATA[definition multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis and hypersexuality]]></category>

		<category><![CDATA[multiple sclerosis and new and treatment]]></category>

		<category><![CDATA[multiple sclerosis caused by chemicals]]></category>

		<category><![CDATA[multiple sclerosis cis]]></category>

		<category><![CDATA[multiple sclerosis cure 'phase ii']]></category>

		<category><![CDATA[multiple sclerosis fasciculations]]></category>

		<category><![CDATA[multiple sclerosis forum]]></category>

		<category><![CDATA[multiple sclerosis mri]]></category>

		<category><![CDATA[multiple sclerosis or guillain barre]]></category>

		<category><![CDATA[multiple sclerosis posters]]></category>

		<category><![CDATA[multiple sclerosis prognosis]]></category>

		<category><![CDATA[multiple sclerosis specialists]]></category>

		<category><![CDATA[multiple sclerosis swollen feet]]></category>

		<category><![CDATA[multiple sclerosis whole body numbness]]></category>

		<category><![CDATA[multiple sclerosis xocai]]></category>

		<category><![CDATA[mystenia and multiple sclerosis]]></category>

		<category><![CDATA[patients with multiple sclerosis]]></category>

		<category><![CDATA[treatments for multiple sclerosis]]></category>

		<category><![CDATA[vitamin d and multiple sclerosis]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=69</guid>
		<description><![CDATA[&#160;










Barchester Healthcare



            MS deterioration &#8217;slowed by new therapy&#8217;
            Barchester Healthcare
            &#8230;&#160;other&#160;leading&#160;institutions in the state, said: &#34;Previous&#160;research&#160;has shown that treatment with daclizumab reduced&#160;multiple [...]]]></description>
			<content:encoded><![CDATA[<p>&nbsp;<span class="Apple-style-span" style="font-family: sans-serif; font-size: 16px; "></p>
<table cellpadding="0" cellspacing="0" border="0" width="600">
<tbody>
<tr>
<td style="padding-bottom: 1em; ">
<table cellpadding="0" cellspacing="0" border="0" width="80" align="left" style="margin-right: 10px; margin-bottom: 10px; ">
<tbody>
<tr>
<td align="center"><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.barchester.com/Healthcare-News/MS-deterioration-%27slowed-by-new-therapy%27/376/3304&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNEFCk9WFkzX4-uijXdamLhphJdJ0w"><img border="0" src="http://www.barchester.com/barchester/cms_assets/direct_news/x-rays_504_19628264_0_0_11703_300-44926.jpg" alt="" width="80" /></a></td>
</tr>
<tr>
<td align="center"><font size="-2"><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.barchester.com/Healthcare-News/MS-deterioration-%27slowed-by-new-therapy%27/376/3304&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNEFCk9WFkzX4-uijXdamLhphJdJ0w">Barchester Healthcare</a></font></td>
</tr>
</tbody>
</table>
<p>            <a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.barchester.com/Healthcare-News/MS-deterioration-%27slowed-by-new-therapy%27/376/3304&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNEFCk9WFkzX4-uijXdamLhphJdJ0w" style="color: blue; ">MS deterioration &#8217;slowed by new therapy&#8217;</a><br />
            <font size="-1"><font color="#666666">Barchester Healthcare</font><br />
            <b>&#8230;</b>&nbsp;other&nbsp;<b>leading</b>&nbsp;institutions in the state, said: &quot;Previous&nbsp;<b>research</b>&nbsp;has shown that treatment with daclizumab reduced&nbsp;<b>multiple sclerosis</b>&nbsp;disease activity.&nbsp;<b>&#8230;</b><br />
            </font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/msnbc-tv-will-feature-brainstorm-today-2010-02-23%3Freflink%3DMW_news_stmp&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNFt-Oal-gueuZylL1wCBLsmzIsQ5Q" style="color: blue; ">MSNBC TV Will Feature BrainStorm Today</a><br />
            <font size="-1"><font color="#666666">MarketWatch (press release)</font><br />
            The company&#8217;s goal is to find a cure for various neurodegenerative diseases such as Parkinson&#8217;s disease and&nbsp;<b>Multiple Sclerosis</b>&nbsp;through its innovative stem&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/msnbc-tv-will-feature-brainstorm-today-2010-02-23%3Freflink%3DMW_news_stmp&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://wake.mync.com/site/wake/news%257CSports%257CLifestyles/story/48490/Presenting_Sponsors_Announced_for_St__Patty_______s_Run_Green__K&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNHi4ltGzitF5mOlpe0Sp4I0zGyYLg" style="color: blue; ">Presenting Sponsors Announced for St. Patty&#8217;s Run Green 8K</a><br />
            <font size="-1"><font color="#666666">MyNC.com</font><br />
            &quot;What better way to raise money for&nbsp;<b>multiple sclerosis research</b>&nbsp;than a run and activities in Moore Square?&quot; The race includes a competitive 8K run,&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://wake.mync.com/site/wake/news%257CSports%257CLifestyles/story/48490/Presenting_Sponsors_Announced_for_St__Patty_______s_Run_Green__K&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://jobs.thirdsector.co.uk/job/323921/head-of-operations&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNGyenAn2oiWxyBcl_i1H-jDAWLWmg" style="color: blue; ">Head of Operations</a><br />
            <font size="-1"><font color="#666666">Third Sector</font><br />
            The MS Society is the UK&#8217;s&nbsp;<b>leading</b>&nbsp;charity for people living with&nbsp;<b>multiple sclerosis</b>&nbsp;(MS). This devastating neurological condition affects more than 85000&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://jobs.thirdsector.co.uk/job/323921/head-of-operations&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
</tbody>
</table>
<p></span></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/news/multiple-sclerosis-ms-information-and-news/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Multiple Sclerosis (MS) : News and Information</title>
		<link>http://mymslog.com/news/multiple-sclerosis-ms-news-and-information/</link>
		<comments>http://mymslog.com/news/multiple-sclerosis-ms-news-and-information/#comments</comments>
		<pubDate>Wed, 03 Mar 2010 13:49:12 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[News]]></category>

		<category><![CDATA[air cleaners multiple sclerosis]]></category>

		<category><![CDATA[benign sensory multiple sclerosis]]></category>

		<category><![CDATA[causes of multiple sclerosis]]></category>

		<category><![CDATA[cure for multiple sclerosis]]></category>

		<category><![CDATA[diagnosing multiple sclerosis]]></category>

		<category><![CDATA[fluconazole multiple sclerosis]]></category>

		<category><![CDATA[leg pain multiple sclerosis]]></category>

		<category><![CDATA[longest survivor multiple sclerosis]]></category>

		<category><![CDATA[michelle obama and multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis and hair loss]]></category>

		<category><![CDATA[multiple sclerosis and venous malformation]]></category>

		<category><![CDATA[multiple sclerosis can be cured in its early stages]]></category>

		<category><![CDATA[multiple sclerosis cured]]></category>

		<category><![CDATA[multiple sclerosis dental]]></category>

		<category><![CDATA[multiple sclerosis disability]]></category>

		<category><![CDATA[multiple sclerosis exercise]]></category>

		<category><![CDATA[multiple sclerosis homes]]></category>

		<category><![CDATA[multiple sclerosis lesions]]></category>

		<category><![CDATA[multiple sclerosis misdiagnosis]]></category>

		<category><![CDATA[multiple sclerosis shirts]]></category>

		<category><![CDATA[multiple sclerosis wheelchair]]></category>

		<category><![CDATA[myoclonus and multiple sclerosis]]></category>

		<category><![CDATA[network spinal analysis and multiple sclerosis]]></category>

		<category><![CDATA[people with multiple sclerosis]]></category>

		<category><![CDATA[primary progressive multiple sclerosis]]></category>

		<category><![CDATA[stem cell therapy for multiple sclerosis]]></category>

		<category><![CDATA[stem cells for multiple sclerosis]]></category>

		<category><![CDATA[transverse myelitis as a first attack of multiple sclerosis]]></category>

		<category><![CDATA[types of multiple sclerosis]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=67</guid>
		<description><![CDATA[&#160;



Brain blood vessels clue to MS
            Tehran Times
            More than 55% of&#160;multiple sclerosis&#160;patients have been found to have constricted blood&#160;&#8230;&#160;but not proof that this caused MS - as one&#160;leading&#160;expert claims.&#160;&#8230;
    [...]]]></description>
			<content:encoded><![CDATA[<p>&nbsp;<span class="Apple-style-span" style="font-family: sans-serif; font-size: 16px; "></p>
<table cellpadding="0" cellspacing="0" border="0" width="600">
<tbody>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.tehrantimes.com/index_View.asp%3Fcode%3D214736&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNGtVbQdhKk-fFU-8JDW-LZkcwSu3g" style="color: blue; ">Brain blood vessels clue to MS</a><br />
            <font size="-1"><font color="#666666">Tehran Times</font><br />
            More than 55% of&nbsp;<b>multiple sclerosis</b>&nbsp;patients have been found to have constricted blood&nbsp;<b>&#8230;</b>&nbsp;but not proof that this caused MS - as one&nbsp;<b>leading</b>&nbsp;expert claims.&nbsp;<b>&#8230;</b><br />
            </font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.prnewswire.com/news-releases/wright-state-university-boonshoft-school-of-medicine-and-miami-valley-hospital-announce-major-new-initiative-85226047.html&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNE1uSE9R_7HElKSX5pQN-4iMLNSZQ" style="color: blue; ">Wright State University Boonshoft School of Medicine and Miami Valley Hospital&nbsp;<b>&#8230;</b></a><br />
            <font size="-1"><font color="#666666">PR Newswire (press release)</font><br />
            This announcement will place us at the forefront of&nbsp;<b>leading</b>&nbsp;scientific&nbsp;<b>research</b>&nbsp;and positions both Miami Valley and the Boonshoft School of Medicine as&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.prnewswire.com/news-releases/wright-state-university-boonshoft-school-of-medicine-and-miami-valley-hospital-announce-major-new-initiative-85226047.html&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.reuters.com/article/idUSN2218463120100222&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNFi4bwjcNfLHOmoJ1V-IARs2Kc-sQ" style="color: blue; ">Genzyme says Carl Icahn to nominate 4 to its board</a><br />
            <font size="-1"><font color="#666666">Reuters</font><br />
            O), an equally venerable biotech whose&nbsp;<b>multiple sclerosis</b>&nbsp;drug Tysabri has been dogged by safety concerns. Genzyme has been racing &#8212; belatedly &#8212; to&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.reuters.com/article/idUSN2218463120100222&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
</tbody>
</table>
<p></span></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/news/multiple-sclerosis-ms-news-and-information/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Multiple Sclerosis (MS): Latest news</title>
		<link>http://mymslog.com/news/multiple-sclerosis-ms-latest-news/</link>
		<comments>http://mymslog.com/news/multiple-sclerosis-ms-latest-news/#comments</comments>
		<pubDate>Mon, 01 Mar 2010 13:49:05 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[News]]></category>

		<category><![CDATA[adult stem cells multiple sclerosis]]></category>

		<category><![CDATA[benign multiple sclerosis]]></category>

		<category><![CDATA[celebrities with multiple sclerosis]]></category>

		<category><![CDATA[early symptoms multiple sclerosis]]></category>

		<category><![CDATA[importance of exercise multiple sclerosis]]></category>

		<category><![CDATA[is multiple sclerosis fatal]]></category>

		<category><![CDATA[montel williams multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis diagnosis]]></category>

		<category><![CDATA[multiple sclerosis diet]]></category>

		<category><![CDATA[multiple sclerosis foundation]]></category>

		<category><![CDATA[multiple sclerosis signs symptoms]]></category>

		<category><![CDATA[multiple sclerosis society]]></category>

		<category><![CDATA[multiple sclerosis stem cell]]></category>

		<category><![CDATA[multiple sclerosis stem cell therapy]]></category>

		<category><![CDATA[multiple sclerosis stem cells]]></category>

		<category><![CDATA[multiple sclerosis symptoms]]></category>

		<category><![CDATA[multiple sclerosis treatment]]></category>

		<category><![CDATA[multiple sclerosis warning signs]]></category>

		<category><![CDATA[national multiple sclerosis society]]></category>

		<category><![CDATA[pregnancy with multiple sclerosis]]></category>

		<category><![CDATA[secondary progressive multiple sclerosis]]></category>

		<category><![CDATA[signs of multiple sclerosis]]></category>

		<category><![CDATA[stem cell treatment multiple sclerosis]]></category>

		<category><![CDATA[stem cells and multiple sclerosis]]></category>

		<category><![CDATA[stem cells in multiple sclerosis]]></category>

		<category><![CDATA[symptoms of multiple sclerosis]]></category>

		<category><![CDATA[what causes multiple sclerosis]]></category>

		<category><![CDATA[what is multiple sclerosis]]></category>

		<category><![CDATA[who discovered multiple sclerosis]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=65</guid>
		<description><![CDATA[&#160;



Copaxone(R) 15-Year Study in&#160;Multiple Sclerosis&#160;Patients Demonstrates Robust&#160;&#8230;
            MarketWatch (press release)
            The data were published in the February issue of the journal&#160;Multiple Sclerosis. The 15-year clinical study demonstrated that more than 80 percent of&#160;&#8230;
 [...]]]></description>
			<content:encoded><![CDATA[<p>&nbsp;<span class="Apple-style-span" style="font-family: sans-serif; font-size: 16px; "></p>
<table cellpadding="0" cellspacing="0" border="0" width="600">
<tbody>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/copaxoner-15-year-study-in-multiple-sclerosis-patients-demonstrates-robust-long-term-efficacy-and-safety-2010-02-25%3Freflink%3DMW_news_stmp&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNEJoNyGh4HDwuvwoW7yRY4g4qKEIA" style="color: blue; ">Copaxone(R) 15-Year Study in&nbsp;<b>Multiple Sclerosis</b>&nbsp;Patients Demonstrates Robust&nbsp;<b>&#8230;</b></a><br />
            <font size="-1"><font color="#666666">MarketWatch (press release)</font><br />
            The data were published in the February issue of the journal&nbsp;<b>Multiple Sclerosis</b>. The 15-year clinical study demonstrated that more than 80 percent of&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/copaxoner-15-year-study-in-multiple-sclerosis-patients-demonstrates-robust-long-term-efficacy-and-safety-2010-02-25%3Freflink%3DMW_news_stmp&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.walesonline.co.uk/news/wales-news/2010/02/28/fears-ms-sufferers-are-at-risk-from-contaminated-cannabis-91466-25927527/&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNENHl-H63feBQ40a92qThnjQhvh2A" style="color: blue; ">Fears MS sufferers are at risk from contaminated cannabis</a><br />
            <font size="-1"><font color="#666666">WalesOnline</font><br />
            A&nbsp;<b>LEADING</b>&nbsp;cannabis campaigner claims&nbsp;<b>multiple sclerosis</b>&nbsp;sufferers are being driven into the arms of illegal dealers selling the drug laced with glass&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.walesonline.co.uk/news/wales-news/2010/02/28/fears-ms-sufferers-are-at-risk-from-contaminated-cannabis-91466-25927527/&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; "><a rel="nofollow" target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.pressbanner.com/view/full_story/6469058/article-The-Straight-Dope--Time-to-recognize-real-benefits-of-medical-marijuana%3Finstance%3Dhome_community&amp;ct=ga&amp;cd=jINLJEwgXyw&amp;usg=AFQjCNFbjFMYdu7mDjQqT0XM5qrxICztcg" style="color: blue; ">The Straight Dope: Time to recognize real benefits of medical marijuana</a><br />
            <font size="-1"><font color="#666666">San Lorenzo Valley Press-Banner</font><br />
            The timing is propitious in this case, as the Center for Medical Cannabis&nbsp;<b>Research</b>&nbsp;at the University of California &mdash; established in 2000 as a result of&nbsp;<b>&#8230;</b><br />
            <a rel="nofollow" target="_blank" href="http://news.google.com/news/story?ncl=http://www.pressbanner.com/view/full_story/6469058/article-The-Straight-Dope--Time-to-recognize-real-benefits-of-medical-marijuana%3Finstance%3Dhome_community&amp;hl=en"><font color="green">See all stories on this topic</font></a></font></td>
</tr>
<tr>
<td style="padding-bottom: 1em; ">&nbsp;</td>
</tr>
</tbody>
</table>
<p></span></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/news/multiple-sclerosis-ms-latest-news/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Dr. Paolo Zamboni: Chronic cerebrospinal venous insufficiency (CCSVI) and MS (Multiple Sclerosis)</title>
		<link>http://mymslog.com/living-with-multiple-sclerosis/dr-paolo-zamboni-chronic-cerebrospinal-venous-insufficiency-ccsvi-and-ms/</link>
		<comments>http://mymslog.com/living-with-multiple-sclerosis/dr-paolo-zamboni-chronic-cerebrospinal-venous-insufficiency-ccsvi-and-ms/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 03:29:49 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[Living with MS]]></category>

		<category><![CDATA[MS Local Chapters]]></category>

		<category><![CDATA[cause of multiple sclerosis]]></category>

		<category><![CDATA[definition of multiple sclerosis]]></category>

		<category><![CDATA[diagnosing multiple sclerosis]]></category>

		<category><![CDATA[Dr. Paolo Zamboni]]></category>

		<category><![CDATA[early symptoms of ms]]></category>

		<category><![CDATA[early symptoms of multiple sclerosis]]></category>

		<category><![CDATA[first symptoms of ms]]></category>

		<category><![CDATA[first symptoms of multiple sclerosis]]></category>

		<category><![CDATA[iagnosis of multiple sclerosis]]></category>

		<category><![CDATA[incidence of multiple sclerosis]]></category>

		<category><![CDATA[ms cure]]></category>

		<category><![CDATA[MS research]]></category>

		<category><![CDATA[ms symptoms]]></category>

		<category><![CDATA[ms treatment]]></category>

		<category><![CDATA[multiple sc]]></category>

		<category><![CDATA[multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis and diet]]></category>

		<category><![CDATA[multiple sclerosis and nutrition]]></category>

		<category><![CDATA[multiple sclerosis and physical therapy]]></category>

		<category><![CDATA[multiple sclerosis and symptoms]]></category>

		<category><![CDATA[multiple sclerosis brain]]></category>

		<category><![CDATA[multiple sclerosis canada]]></category>

		<category><![CDATA[multiple sclerosis cause]]></category>

		<category><![CDATA[multiple sclerosis causes]]></category>

		<category><![CDATA[multiple sclerosis cure]]></category>

		<category><![CDATA[multiple sclerosis diagnosis]]></category>

		<category><![CDATA[multiple sclerosis doctors]]></category>

		<category><![CDATA[multiple sclerosis early symptoms]]></category>

		<category><![CDATA[multiple sclerosis eye]]></category>

		<category><![CDATA[multiple sclerosis fatigue]]></category>

		<category><![CDATA[multiple sclerosis foundation]]></category>

		<category><![CDATA[multiple sclerosis genetic]]></category>

		<category><![CDATA[multiple sclerosis incidence]]></category>

		<category><![CDATA[multiple sclerosis lesions]]></category>

		<category><![CDATA[multiple sclerosis mri]]></category>

		<category><![CDATA[multiple sclerosis numbness]]></category>

		<category><![CDATA[multiple sclerosis pain]]></category>

		<category><![CDATA[multiple sclerosis prevalence]]></category>

		<category><![CDATA[multiple sclerosis prognosis]]></category>

		<category><![CDATA[multiple sclerosis research]]></category>

		<category><![CDATA[multiple sclerosis society]]></category>

		<category><![CDATA[multiple sclerosis stories]]></category>

		<category><![CDATA[multiple sclerosis support]]></category>

		<category><![CDATA[multiple sclerosis symptom]]></category>

		<category><![CDATA[multiple sclerosis treatment]]></category>

		<category><![CDATA[multiple sclerosis treatments]]></category>

		<category><![CDATA[multiple sclerosis types]]></category>

		<category><![CDATA[muscular sclerosis]]></category>

		<category><![CDATA[mutiple sclerosis]]></category>

		<category><![CDATA[national ms society]]></category>

		<category><![CDATA[pictures of multiple sclerosis]]></category>

		<category><![CDATA[prevalence of multiple sclerosis]]></category>

		<category><![CDATA[prognosis of multiple sclerosis]]></category>

		<category><![CDATA[signs and symptoms of ms]]></category>

		<category><![CDATA[signs and symptoms of multiple sclerosis]]></category>

		<category><![CDATA[signs of multiple sclerosis]]></category>

		<category><![CDATA[symptom of multiple sclerosis]]></category>

		<category><![CDATA[symptoms multiple sclerosis]]></category>

		<category><![CDATA[symptoms of ms]]></category>

		<category><![CDATA[symptoms of ms disease]]></category>

		<category><![CDATA[symptoms of multiple sclerosis]]></category>

		<category><![CDATA[treatment of multiple sclerosis]]></category>

		<category><![CDATA[treatments of multiple sclerosis]]></category>

		<category><![CDATA[types of multiple sclerosis]]></category>

		<category><![CDATA[what are symptoms of multiple sclerosis]]></category>

		<category><![CDATA[what are the symptoms of ms]]></category>

		<category><![CDATA[what are the symptoms of multiple sclerosis]]></category>

		<category><![CDATA[what causes multiple sclerosis]]></category>

		<category><![CDATA[what is ms]]></category>

		<category><![CDATA[what is multiple sclerosis]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=56</guid>
		<description><![CDATA[Chronic cerebrospinal venous insufficiency (CCSVI) and MS

&#160;
Overview and FAQ
November 2009
&#160;
&#34;As President and CEO of the MS Society, I am aware of the tremendous interest across Canada and around the world caused by the recent news coverage of the CCSVI study. Indeed I share your excitement and hope in the preliminary findings of this study. I [...]]]></description>
			<content:encoded><![CDATA[<p><span style="font-size: 10pt; font-weight: bold">Chronic cerebrospinal venous insufficiency (CCSVI) and MS</span></p>
<div>
<div><span style="font-size: 10pt; font-weight: bold"><font color="#0000ff">&nbsp;</font></span></div>
<div><span style="font-size: 10pt; font-weight: bold">Overview and FAQ</span></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">November 2009</span></font></b></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">&quot;As President and CEO of the MS Society, I am aware of the tremendous interest across Canada and around the world caused by the recent news coverage of the CCSVI study. Indeed I share your excitement and hope in the preliminary findings of this study. I also celebrate and respect the integrity of our research funding programs which will continue to ensure that the very best projects are selected and supported. For more detail on this process please <a title="http://www.mssociety.ca/en/research/" href="http://www.mssociety.ca/en/research/"><font color="#0000ff">link here</font></a>.&quot;</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">Yves Savoie</span></font></div>
<div><font size="2"><span style="font-size: 10pt">President and chief executive officer</span></font></div>
<div><font size="2"><span style="font-size: 10pt">President, Ontario Division</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">Overview</span></font></b></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">Chronic cerebrospinal venous insufficiency (CCSVI) describes a hypothetical disruption of blood flow in which the venous system is not able to efficiently remove blood from the central nervous system resulting in increased pressure in the veins of the brain and spinal cord which in turn results in damage to these areas.&nbsp; Recent reports have revived the idea of an association between inadequate venous drainage and multiple sclerosis.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society of Canada is aware of recent reports on the subject of CCSVI that may open up new avenues of research including new therapies for MS.&nbsp; While the early data shows promise, it is important to acknowledge that the concepts surrounding CCSVI and multiple sclerosis are still relatively new and requires replication and validation in much larger, well-designed scientific studies before they can be accepted as established. </span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society of Canada is closely monitoring all research related to CCSVI and will post new information on <a title="http://www.mssociety.ca/" href="http://www.mssociety.ca/">www.mssociety.ca</a> </span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">FAQ</span></font></b></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">1.&nbsp; What is CCSVI?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Chronic cerebrospinal venous insufficiency (CCSVI) is a term used to describe a hypothetical situation in which the venous system is not able to efficiently remove blood from the central nervous system. It is stated that this is related to narrowing of small venous structures in the neck, chest and spine.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">2. Why is there a sudden interest in CCSVI and MS?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Media attention and a few recent reports have revived speculation about a possible dysfunction of brain blood flow and/or drainage in individuals who have MS. In particular, one study involving 65 people with different types of MS compared with 235 people who were healthy or who had other neurological disorders, a robust relationship was found between having MS and signs of venous insufficiency &ndash; suggesting that blood drainage by veins may be impaired, contributing to nerve tissue damage. This study, by Paulo Zamboni, MD (University of Ferrara - Ferrara, Italy) and colleagues, was published in 2009. (J Neurology Neurosurgery Psychiatry. 2009 Apr; 80 (4): 392-9. Epub. 2008 Dec 5.)</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">The investigators called this venous obstruction &ldquo;chronic cerebrospinal venous insufficiency&rdquo; or CCSVI. The treatment status of the people with MS did not appear to influence whether they showed signs of CCSVI. The authors speculate that the abnormal venous drainage of blood back from the brain and spine might set off the inflammation and immune-mediated damage that is characteristic of MS.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">3. Do these reports of a possible association between insufficient vein drainage and MS mean that MS is caused by venous insufficiency?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Not necessarily. Based on what has been published so far, we can only say that MS may occur in association with impaired venous drainage of the central nervous system. This impairment, if truly present, could cause MS but it is possible that it is incidental to the disease. More study is needed.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">4.&nbsp; How has CCSVI been treated?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Researchers involved with CCSVI have used &ldquo;balloons&rdquo; to open up narrowed veins or inserted stents into veins to help keep them open. This work is at a very early stage and has been performed on only a very small number of patients.&nbsp; It requires passing a catheter (wire) through the veins to the area of venous narrowing so that it can be widened and is not without risk including the chance of bleeding or the formation of abnormal blood clots.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">5.&nbsp; Will the treatment of CCSVI be useful for the various forms of MS?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Whether this type of treatment will be useful in any form of MS is currently unknown as research on this question is at a very early stage.&nbsp; Much more work needs to be done.</span></font></div>
<div><font size="2"><span style="font-size: 10pt">&nbsp;&nbsp; </span></font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">6.&nbsp; What is the MS Society&rsquo;s position on CCSVI?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society of Canada believes that this topic opens up new avenues of research in MS including the possibility of new treatments. Although the early data are of great interest, it is important to acknowledge that the concept of CCSVI as a cause of MS and the use of stents or balloons to widen veins as treatments, are ideas that are far from being accepted by most researchers in the field. The early results need to be replicated and validated in much larger well-designed studies.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society of Canada is closely monitoring all research related to CCSVI and will post new information on www.mssociety.ca.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">7.&nbsp; Does the MS Society currently fund research into CCSVI?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">At the present time, the MS Society of Canada does not fund research into CCSVI but it is open to the possibility of funding appropriately designed studies that address this topic.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society of Canada welcomes research proposals from qualified investigators based in Canadian institutions whose research questions are relevant to multiple sclerosis. All proposals received are thoroughly evaluated by expert volunteer scientific peer review panels from major academic research institutions. Proposals are evaluated for their scientific merit and relevance to the field of MS. This same policy would apply to potential research projects on the topic of CCSVI and MS.</span></font></div>
<div><font size="2">&nbsp;</font></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">8.&nbsp; Does the MS Society recommend people travel to get potential treatments related to this new idea?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">The MS Society believes that this is a question to be addressed by the individual to their neurologist/physician. It is noteworthy that the treatment ideas in question are very new and not scientifically established.</span></font></div>
<div><b><font size="2">&nbsp;</font></b></div>
<div><b><font size="2"><span style="font-size: 10pt; font-weight: bold">9.&nbsp; I have MS. Should I be tested for signs of CCSVI?</span></font></b></div>
<div><font size="2"><span style="font-size: 10pt">Please consult your neurologist/physician for medical advice on this topic.</span></font></div>
</div>
<p><a href="http://www.mssociety.ca">MS Society Canada</a></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/living-with-multiple-sclerosis/dr-paolo-zamboni-chronic-cerebrospinal-venous-insufficiency-ccsvi-and-ms/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Why is the Durham Region MS Society looking for you?</title>
		<link>http://mymslog.com/ms-local-chapters/why-is-the-durham-region-ms-society-looking-for-you/</link>
		<comments>http://mymslog.com/ms-local-chapters/why-is-the-durham-region-ms-society-looking-for-you/#comments</comments>
		<pubDate>Mon, 21 Sep 2009 16:00:05 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[MS Local Chapters]]></category>

		<category><![CDATA[about multiple sclerosis]]></category>

		<category><![CDATA[acupuncture multiple sclerosis]]></category>

		<category><![CDATA[articles on multiple sclerosis]]></category>

		<category><![CDATA[cause of multiple sclerosis]]></category>

		<category><![CDATA[causes of multiple sclerosis]]></category>

		<category><![CDATA[celebrities with multiple sclerosis]]></category>

		<category><![CDATA[copaxone multiple sclerosis]]></category>

		<category><![CDATA[cure for multiple sclerosis]]></category>

		<category><![CDATA[cures for multiple sclerosis]]></category>

		<category><![CDATA[define multiple sclerosis]]></category>

		<category><![CDATA[definition of multiple sclerosis]]></category>

		<category><![CDATA[diagnosing multiple sclerosis]]></category>

		<category><![CDATA[diagnosis of multiple sclerosis]]></category>

		<category><![CDATA[diet for multiple sclerosis]]></category>

		<category><![CDATA[early signs of multiple sclerosis]]></category>

		<category><![CDATA[early symptoms of multiple sclerosis]]></category>

		<category><![CDATA[effects of multiple sclerosis]]></category>

		<category><![CDATA[end stage multiple sclerosis]]></category>

		<category><![CDATA[exercises for multiple sclerosis]]></category>

		<category><![CDATA[famous people with multiple sclerosis]]></category>

		<category><![CDATA[genetics multiple sclerosis]]></category>

		<category><![CDATA[heal multiple sclerosis]]></category>

		<category><![CDATA[history of multiple sclerosis]]></category>

		<category><![CDATA[incidence of multiple sclerosis]]></category>

		<category><![CDATA[info on multiple sclerosis]]></category>

		<category><![CDATA[information about multiple sclerosis]]></category>

		<category><![CDATA[information on multiple sclerosis]]></category>

		<category><![CDATA[interferon multiple sclerosis]]></category>

		<category><![CDATA[Living with MS]]></category>

		<category><![CDATA[mild multiple sclerosis]]></category>

		<category><![CDATA[ms multiple sclerosis]]></category>

		<category><![CDATA[ms online support]]></category>

		<category><![CDATA[ms support]]></category>

		<category><![CDATA[ms support groups]]></category>

		<category><![CDATA[multiple sclerosis age]]></category>

		<category><![CDATA[multiple sclerosis alternative medicine]]></category>

		<category><![CDATA[multiple sclerosis alternative treatment]]></category>

		<category><![CDATA[multiple sclerosis and diet]]></category>

		<category><![CDATA[multiple sclerosis and exercise]]></category>

		<category><![CDATA[multiple sclerosis and pregnancy]]></category>

		<category><![CDATA[multiple sclerosis association]]></category>

		<category><![CDATA[multiple sclerosis association of america]]></category>

		<category><![CDATA[multiple sclerosis attack]]></category>

		<category><![CDATA[multiple sclerosis blog]]></category>

		<category><![CDATA[multiple sclerosis books]]></category>

		<category><![CDATA[multiple sclerosis canada]]></category>

		<category><![CDATA[multiple sclerosis causes]]></category>

		<category><![CDATA[multiple sclerosis center]]></category>

		<category><![CDATA[multiple sclerosis centers]]></category>

		<category><![CDATA[multiple sclerosis chat room]]></category>

		<category><![CDATA[multiple sclerosis chat rooms]]></category>

		<category><![CDATA[multiple sclerosis children]]></category>

		<category><![CDATA[multiple sclerosis cognitive]]></category>

		<category><![CDATA[multiple sclerosis community]]></category>

		<category><![CDATA[multiple sclerosis cure]]></category>

		<category><![CDATA[multiple sclerosis cures]]></category>

		<category><![CDATA[multiple sclerosis death]]></category>

		<category><![CDATA[multiple sclerosis definition]]></category>

		<category><![CDATA[multiple sclerosis depression]]></category>

		<category><![CDATA[multiple sclerosis diagnosis]]></category>

		<category><![CDATA[multiple sclerosis diagnosis symptoms]]></category>

		<category><![CDATA[multiple sclerosis diet]]></category>

		<category><![CDATA[multiple sclerosis disability]]></category>

		<category><![CDATA[multiple sclerosis disease]]></category>

		<category><![CDATA[multiple sclerosis doctors]]></category>

		<category><![CDATA[multiple sclerosis drugs]]></category>

		<category><![CDATA[multiple sclerosis early signs]]></category>

		<category><![CDATA[multiple sclerosis early symptom]]></category>

		<category><![CDATA[multiple sclerosis early symptoms]]></category>

		<category><![CDATA[multiple sclerosis education]]></category>

		<category><![CDATA[multiple sclerosis effects]]></category>

		<category><![CDATA[multiple sclerosis emedicine]]></category>

		<category><![CDATA[multiple sclerosis epidemiology]]></category>

		<category><![CDATA[multiple sclerosis exacerbation]]></category>

		<category><![CDATA[multiple sclerosis exercise]]></category>

		<category><![CDATA[multiple sclerosis exercises]]></category>

		<category><![CDATA[multiple sclerosis fact]]></category>

		<category><![CDATA[multiple sclerosis facts]]></category>

		<category><![CDATA[multiple sclerosis fatigue]]></category>

		<category><![CDATA[multiple sclerosis forum]]></category>

		<category><![CDATA[multiple sclerosis forums]]></category>

		<category><![CDATA[multiple sclerosis funding]]></category>

		<category><![CDATA[multiple sclerosis genetic]]></category>

		<category><![CDATA[multiple sclerosis guide]]></category>

		<category><![CDATA[multiple sclerosis headache]]></category>

		<category><![CDATA[multiple sclerosis healing]]></category>

		<category><![CDATA[multiple sclerosis hearing loss]]></category>

		<category><![CDATA[multiple sclerosis heat]]></category>

		<category><![CDATA[multiple sclerosis help]]></category>

		<category><![CDATA[multiple sclerosis herbs]]></category>

		<category><![CDATA[multiple sclerosis hereditary]]></category>

		<category><![CDATA[multiple sclerosis history]]></category>

		<category><![CDATA[multiple sclerosis incidence]]></category>

		<category><![CDATA[multiple sclerosis information]]></category>

		<category><![CDATA[multiple sclerosis journal]]></category>

		<category><![CDATA[multiple sclerosis lesions]]></category>

		<category><![CDATA[multiple sclerosis life]]></category>

		<category><![CDATA[multiple sclerosis life expectancy]]></category>

		<category><![CDATA[multiple sclerosis marijuana]]></category>

		<category><![CDATA[multiple sclerosis medication]]></category>

		<category><![CDATA[multiple sclerosis medications]]></category>

		<category><![CDATA[multiple sclerosis medicine]]></category>

		<category><![CDATA[multiple sclerosis medicines]]></category>

		<category><![CDATA[multiple sclerosis message boards]]></category>

		<category><![CDATA[multiple sclerosis mri]]></category>

		<category><![CDATA[multiple sclerosis myelin]]></category>

		<category><![CDATA[multiple sclerosis natural]]></category>

		<category><![CDATA[multiple sclerosis natural treatment]]></category>

		<category><![CDATA[multiple sclerosis new treatment]]></category>

		<category><![CDATA[multiple sclerosis news]]></category>

		<category><![CDATA[multiple sclerosis nutrition]]></category>

		<category><![CDATA[multiple sclerosis onset]]></category>

		<category><![CDATA[multiple sclerosis pain]]></category>

		<category><![CDATA[multiple sclerosis pathophysiology]]></category>

		<category><![CDATA[multiple sclerosis patients]]></category>

		<category><![CDATA[multiple sclerosis personal stories]]></category>

		<category><![CDATA[multiple sclerosis physical therapy]]></category>

		<category><![CDATA[multiple sclerosis pictures]]></category>

		<category><![CDATA[multiple sclerosis pregnancy]]></category>

		<category><![CDATA[multiple sclerosis prevalence]]></category>

		<category><![CDATA[multiple sclerosis prevention]]></category>

		<category><![CDATA[multiple sclerosis prognosis]]></category>

		<category><![CDATA[multiple sclerosis research]]></category>

		<category><![CDATA[multiple sclerosis resources]]></category>

		<category><![CDATA[multiple sclerosis risk factors]]></category>

		<category><![CDATA[multiple sclerosis signs]]></category>

		<category><![CDATA[multiple sclerosis signs and symptoms]]></category>

		<category><![CDATA[multiple sclerosis society]]></category>

		<category><![CDATA[multiple sclerosis society national]]></category>

		<category><![CDATA[multiple sclerosis spasticity]]></category>

		<category><![CDATA[multiple sclerosis specialist]]></category>

		<category><![CDATA[multiple sclerosis specialists]]></category>

		<category><![CDATA[multiple sclerosis stages]]></category>

		<category><![CDATA[multiple sclerosis statistics]]></category>

		<category><![CDATA[multiple sclerosis stem cell]]></category>

		<category><![CDATA[multiple sclerosis stem cells]]></category>

		<category><![CDATA[multiple sclerosis stories]]></category>

		<category><![CDATA[multiple sclerosis stress]]></category>

		<category><![CDATA[multiple sclerosis supplements]]></category>

		<category><![CDATA[multiple sclerosis symptom]]></category>

		<category><![CDATA[multiple sclerosis symptoms]]></category>

		<category><![CDATA[multiple sclerosis symptons]]></category>

		<category><![CDATA[multiple sclerosis test]]></category>

		<category><![CDATA[multiple sclerosis testing]]></category>

		<category><![CDATA[multiple sclerosis tests]]></category>

		<category><![CDATA[multiple sclerosis therapies]]></category>

		<category><![CDATA[multiple sclerosis therapy]]></category>

		<category><![CDATA[multiple sclerosis treatment]]></category>

		<category><![CDATA[multiple sclerosis treatments]]></category>

		<category><![CDATA[multiple sclerosis types]]></category>

		<category><![CDATA[multiple sclerosis video]]></category>

		<category><![CDATA[multiple sclerosis walk]]></category>

		<category><![CDATA[multiple symptoms]]></category>

		<category><![CDATA[multiplesclerosis]]></category>

		<category><![CDATA[muscular sclerosis]]></category>

		<category><![CDATA[national multiple sclerosis]]></category>

		<category><![CDATA[Nutrition]]></category>

		<category><![CDATA[nutrition and multiple sclerosis]]></category>

		<category><![CDATA[pain and multiple sclerosis]]></category>

		<category><![CDATA[pathophysiology of multiple sclerosis]]></category>

		<category><![CDATA[pediatric multiple sclerosis]]></category>

		<category><![CDATA[people with multiple sclerosis]]></category>

		<category><![CDATA[pictures of multiple sclerosis]]></category>

		<category><![CDATA[prevalence of multiple sclerosis]]></category>

		<category><![CDATA[primary progressive multiple sclerosis]]></category>

		<category><![CDATA[progressive multiple sclerosis]]></category>

		<category><![CDATA[rebif multiple sclerosis]]></category>

		<category><![CDATA[relapsing multiple sclerosis]]></category>

		<category><![CDATA[relapsing remitting multiple sclerosis]]></category>

		<category><![CDATA[research on multiple sclerosis]]></category>

		<category><![CDATA[sclerosis symptoms]]></category>

		<category><![CDATA[sclerosis treatment]]></category>

		<category><![CDATA[secondary progressive multiple sclerosis]]></category>

		<category><![CDATA[signs and symptoms of multiple sclerosis]]></category>

		<category><![CDATA[signs of multiple sclerosis]]></category>

		<category><![CDATA[stages of multiple sclerosis]]></category>

		<category><![CDATA[supplements for multiple sclerosis]]></category>

		<category><![CDATA[symptoms and multiple sclerosis]]></category>

		<category><![CDATA[symptoms for multiple sclerosis]]></category>

		<category><![CDATA[symptoms of multiple sclerosis]]></category>

		<category><![CDATA[symptons of multiple sclerosis]]></category>

		<category><![CDATA[symtoms of multiple sclerosis]]></category>

		<category><![CDATA[test for multiple sclerosis]]></category>

		<category><![CDATA[tests for multiple sclerosis]]></category>

		<category><![CDATA[the national multiple sclerosis society]]></category>

		<category><![CDATA[treatment for multiple sclerosis]]></category>

		<category><![CDATA[treatment of multiple sclerosis]]></category>

		<category><![CDATA[treatments for multiple sclerosis]]></category>

		<category><![CDATA[types of multiple sclerosis]]></category>

		<category><![CDATA[vitamin d and multiple sclerosis]]></category>

		<category><![CDATA[vitamin d multiple sclerosis]]></category>

		<category><![CDATA[what are the symptoms of multiple sclerosis]]></category>

		<category><![CDATA[what causes multiple sclerosis]]></category>

		<category><![CDATA[what is multiple sclerosis]]></category>

		<category><![CDATA[yoga and multiple sclerosis]]></category>

		<category><![CDATA[yoga for multiple sclerosis]]></category>

		<category><![CDATA[yoga multiple sclerosis]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=50</guid>
		<description><![CDATA[&#160;The Durham Region Chapter of the Multiple Sclerosis Society of Canada is currently recruiting for a Chair Person. The Chapter Chair is a member of the chapter executive team and is responsible for presiding at all meetings, oversees the general affairs of the Chapter and ensure all orders of the Board of Directors are carried [...]]]></description>
			<content:encoded><![CDATA[<p>&nbsp;<span style="font-family:Arial">The <b>Durham Region Chapter of the Multiple Sclerosis Society of Canada</b> is currently recruiting for a Chair Person. The Chapter Chair is a member of the chapter executive team and is responsible for presiding at all meetings, oversees the general affairs of the Chapter and ensure all orders of the Board of Directors are carried out. Candidates should be members of the CCFC (or willing to obtain membership), have basic knowledge of board functions, excellent organizational skills, a sense of responsibility and bondable. To apply for this position and obtain further information, contact <strong><span style="font-family:Arial">Debbie at (905) 683-0388 </span></strong>or by email at </span><span class="apple-style-span"><span style="font-size:8.0pt;font-family:Verdana;color:black"><a ymailto="mailto:jane.doe@mssociety.ca" href="mailto:ms.durham@bellnet.ca"><span style="font-size:12.0pt;color:#41519A">ms.durham@bellnet.ca</span></a></span></span></p>
<p class="MsoNormal"><o:p></o:p></p>
<p class="MsoNormal"><o:p>&nbsp;</o:p></p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/ms-local-chapters/why-is-the-durham-region-ms-society-looking-for-you/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Multiple Sclerosis Society of Canada – Durham Region Chapter</title>
		<link>http://mymslog.com/ms-local-chapters/multiple-sclerosis-society-durham-region-chapter/</link>
		<comments>http://mymslog.com/ms-local-chapters/multiple-sclerosis-society-durham-region-chapter/#comments</comments>
		<pubDate>Wed, 24 Jun 2009 06:00:42 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[MS Local Chapters]]></category>

		<category><![CDATA[ajax]]></category>

		<category><![CDATA[clarington]]></category>

		<category><![CDATA[durham region]]></category>

		<category><![CDATA[MS Durham Region]]></category>

		<category><![CDATA[MS research]]></category>

		<category><![CDATA[MS Society]]></category>

		<category><![CDATA[multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis durham region]]></category>

		<category><![CDATA[newly diagnosed]]></category>

		<category><![CDATA[oshawa]]></category>

		<category><![CDATA[Pickering]]></category>

		<category><![CDATA[scugog]]></category>

		<category><![CDATA[uxbridge]]></category>

		<category><![CDATA[whitby]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=40</guid>
		<description><![CDATA[The Multiple Sclerosis society of Canada has many local chapters to assist at the community level.&#160; Just east of Toronto Ontario is the community of Durham Region consisting of Pickering, Ajax, Whitby, Oshawa, Uxbridge, Brock, Scugog and Clarington.&#160; Having a local chapter in the Durham Region helps those inflicted with Multiple Sclerosis as well supports [...]]]></description>
			<content:encoded><![CDATA[<p>The Multiple Sclerosis society of Canada has many local chapters to assist at the community level.&nbsp; Just east of Toronto Ontario is the community of Durham Region consisting of Pickering, Ajax, Whitby, Oshawa, Uxbridge, Brock, Scugog and Clarington.&nbsp; Having a local chapter in the Durham Region helps those inflicted with Multiple Sclerosis as well supports their caregivers.&nbsp; If you are newly diagnosed and need information on Multiple Sclerosis and the various options available to you contact the staff at the MS Society Durham Chapter.&nbsp; They have a wealth of information that is designed to help you.&nbsp; Various events and fundraisers throughout the year help to raise funds that help both the local community and the fight to end MS.&nbsp;</p>
<p>If you are suffering from Multiple Sclerosis or know someone who is, contact you local Chapter In Durham Region and get involved.&nbsp;&nbsp;&nbsp;</p>
<p>You can contact the <strong>Multiple Sclerosis Durham Region Chapter </strong>directly at;</p>
<p>#6-400 Dundas St W<br />
Whitby, ON L1N 2M7<br />
Telephone : +1 (905) 668-0388,<br />
Fax : +1 (905) 668-6904<br />
<a href="mailto:ms.durham@bellnet.ca">ms.durham@bellnet.ca</a><br />
&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/ms-local-chapters/multiple-sclerosis-society-durham-region-chapter/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Documentary Captures Life in a Wheelchair</title>
		<link>http://mymslog.com/living-with-multiple-sclerosis/documentary-captures-life-in-a-wheelchair/</link>
		<comments>http://mymslog.com/living-with-multiple-sclerosis/documentary-captures-life-in-a-wheelchair/#comments</comments>
		<pubDate>Fri, 27 Mar 2009 17:54:12 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[Living with MS]]></category>

		<category><![CDATA[disability]]></category>

		<category><![CDATA[MS Durham Region]]></category>

		<category><![CDATA[ms wheelchair]]></category>

		<category><![CDATA[multiple sclerosis]]></category>

		<category><![CDATA[multiple sclerosis durham region]]></category>

		<category><![CDATA[newly diagnosed]]></category>

		<guid isPermaLink="false">http://mymslog.com/?p=30</guid>
		<description><![CDATA[by Catherine Mabe

    window.addEvent(&#8217;domready&#8217;, function() {
        //(id of img elem, id of title elem) passed as arg to constructor
        PB.init( &#8216;Feature&#8217;, &#8216;Caption&#8217; );
        PB.photos.push( new PhotoObj(&#8217;/articles/articleImage.aspx?postid=26823&#038;postimageid=b8305351-235a-4ec2-ae0d-a63dac445559&#8242;, &#8221; ) );
   [...]]]></description>
			<content:encoded><![CDATA[<p><span style="color: #999999">by Catherine Mabe</span></p>
<p><span><SCRIPT type=text/javascript><br />
    window.addEvent(&#8217;domready&#8217;, function() {<br />
        //(id of img elem, id of title elem) passed as arg to constructor<br />
        PB.init( &#8216;Feature&#8217;, &#8216;Caption&#8217; );<br />
        PB.photos.push( new PhotoObj(&#8217;/articles/articleImage.aspx?postid=26823&#038;postimageid=b8305351-235a-4ec2-ae0d-a63dac445559&#8242;, &#8221; ) );<br />
        PB.preload();</p>
<p>        var indx, linkList = $(&#8217;PhotoPagination&#8217;).getElements(&#8217;li&#8217;);<br />
        linkList.each(function(elem) {<br />
            elem.addEvent(&#8217;mousedown&#8217;, function(){<br />
                //move the &#8216;Current&#8217; class<br />
                var current = $(&#8217;PhotoPagination&#8217;).getElements(&#8217;li[class=Current]&#8216;);<br />
                current.removeProperty(&#8217;class&#8217;);<br />
                elem.setProperty(&#8217;class&#8217;, &#8216;Current&#8217;);<br />
                //grab the index<br />
                indx = elem.innerHTML;<br />
                //now cycle the image<br />
                PB.linkselect( indx );<br />
            });<br />
        });<br />
    });<br />
</SCRIPT>What could you learn if you gave a few people cameras and asked them to show you their lives? That&rsquo;s the question writer, director, and producer Gretchen Berland set out to answer when she mounted cameras to the wheelchairs of three Los Angeles residents and gave them free rein to film their daily lives.</span></p>
<div>Two years later, Berland had 212 hours of tape, which was a complex mixture of wit, sadness, happiness, frustration, humor . . .&nbsp; and everything in-between. When cut down, the tape (which gives viewers a real, first-person perspective of what it&rsquo;s like for the wheelchair-bound to navigate through life) was transformed into the one-hour documentary, <i>Rolling: Life in a Wheelchair</i>.</div>
<div>&nbsp;</div>
<div><b>The Main Subjects of <i>Rolling</i>:</b></div>
<ul>
<li><b>Galen Buckwalter</b>, a clinical psychologist who ran &ldquo;for the sheer fun of it&rdquo; until, he says, &ldquo;. . . a smooth swan dive on a nice summer day ended when I hit a rock and was left paralyzed from the neck down. I&rsquo;ve used a wheelchair for 30 years now.&rdquo;</li>
<li><b>Ernie Wallengren</b>, a 48-year-old TV writer with five children. Wallengren suffers from ALS (Lou Gehrig&#8217;s disease) and can no longer walk as a result. &ldquo;I am bored beyond belief,&rdquo; he says of life with the disease. &ldquo;The boredom&mdash;boy, is that the mainstay of life with ALS.&rdquo;&nbsp;</li>
<li><b>Vicki Elman</b>, whose battle with multiple sclerosis (MS) ended her career as the business manager for a department at the UCLA School of Medicine. One of the most heart-wrenching scenes in this film centers on Elman&rsquo;s intense frustration over the malfunction of her motorized wheelchair when she is dropped off 10 feet from the entrance to her home. She remains there as the sun sets because a company policy prevents the access van driver from helping her to her door.</li>
<li>All three subjects were involved in editing the film to ensure that the reality of their everyday moments was preserved and presented in the way the film intended. Berland is quick to point out that since her approach to <i>Rolling</i> was far from traditional, aspects of the film&rsquo;s production were untraditional as well.</li>
</ul>
<div>Berland hopes the film&rsquo;s real message resonates far and wide, from the masses that catch it on public television to health policy decision-makers. She is planning a screening for members of Congress in Washington, D.C.</div>
<div>Produced, written, and directed by Berland, an assistant professor of medicine at Yale University, Rolling is presented on public television by Thirteen/WNET New York and distributed by American Public Television (check local listings for show times.).</div>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/living-with-multiple-sclerosis/documentary-captures-life-in-a-wheelchair/feed/</wfw:commentRss>
		</item>
		<item>
		<title>My first blog</title>
		<link>http://mymslog.com/sunshines-blog/28/</link>
		<comments>http://mymslog.com/sunshines-blog/28/#comments</comments>
		<pubDate>Tue, 24 Mar 2009 20:31:04 +0000</pubDate>
		<dc:creator>Cisco</dc:creator>
		
		<category><![CDATA[Sunshines Blog]]></category>

		<guid isPermaLink="false">http://mymslog.com/sunshines-blog/28/</guid>
		<description><![CDATA[First blog for Sunshine
]]></description>
			<content:encoded><![CDATA[<p>First blog for Sunshine</p>
]]></content:encoded>
			<wfw:commentRss>http://mymslog.com/sunshines-blog/28/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
